Osteonecrosis of the jaw is a rare but serious condition where the jawbone tissue dies and becomes exposed through the gums. While anyone can develop this condition, it occurs most often in people receiving certain medications for cancer or bone loss. Understanding how to prevent, recognize, and treat this complication is essential for maintaining quality of life during and after treatment.

Understanding Treatment Goals for Osteonecrosis of the Jaw

When osteonecrosis of the jaw develops, treatment focuses on several important goals: controlling pain, preventing infection, stopping further bone death, and helping patients maintain their ability to eat and speak comfortably. The approach to treating this condition depends heavily on how advanced it is when doctors first discover it, and on the overall health of the patient. Some people may have no symptoms at all in the early stages, while others experience significant pain and visible bone exposure in their mouth.^[1]

Healthcare providers recognize that osteonecrosis of the jaw requires a careful balance between medical and dental care. Because the condition most commonly occurs in people taking medications for serious health problems like cancer or severe bone loss, doctors must consider the benefits of continuing these life-saving treatments against the risk of worsening jaw problems. The main goal is not always to cure the condition completely, but rather to improve the patient’s comfort and prevent complications that could severely impact their daily life.^[2]

Standard treatments have been developed based on years of experience treating patients with this condition. At the same time, researchers continue to explore new approaches to help people recover more quickly and completely. Treatment plans are highly individualized, taking into account factors such as which medications the person is taking, whether they have cancer, how long they’ve been on treatment, and their dental health history.^[3]

Standard Treatment Approaches

The standard treatment for osteonecrosis of the jaw starts with the simplest and least invasive approaches, particularly for people in the early stages of the condition. Most patients who develop this complication while taking medications for bone loss from conditions like osteoporosis can be successfully managed without surgery. The first line of treatment typically involves conservative care, which means using methods that don’t require cutting into bone or tissue.^[2]

Antibiotics play a central role in managing osteonecrosis of the jaw because the exposed bone often becomes infected with bacteria from the mouth. These medications help control infection and reduce the painful swelling and pus drainage that many patients experience. Doctors usually prescribe antibiotics that work well against the types of bacteria commonly found in the mouth. The duration of antibiotic treatment varies depending on how severe the infection is and how well the patient responds.^[3]

Antimicrobial mouth rinses are another cornerstone of standard treatment. Patients are instructed to use special mouth rinses, often containing chlorhexidine or other antimicrobial agents, multiple times each day. These rinses help reduce the number of bacteria in the mouth, which can prevent new infections and help existing infections heal. Some specialists describe these as “super-powered” versions of regular mouthwash. Patients may also be taught to gently clean the exposed bone with a cotton swab dipped in the rinse to remove dead tissue and bacteria.^[16]

Pain management is essential for maintaining quality of life during treatment. Healthcare providers prescribe oral analgesics, which are pain-relieving medications taken by mouth. The type and strength of pain medication depends on how much discomfort the patient experiences. Some people need only mild pain relievers, while others with more advanced disease may require stronger medications to control their symptoms.^[3]

For patients with exposed bone that needs protection, dentists may create a mouth guard or special dental appliance. This custom-made device covers the area of exposed bone, protecting it from further trauma during eating and speaking. It also helps prevent irritation from the tongue rubbing against the rough bone surface.^[2]

The approach to the medications that may have caused the osteonecrosis depends greatly on why the person is taking them. For patients receiving high-dose intravenous bisphosphonates as part of cancer treatment, doctors must carefully weigh the benefits of continuing the medication against the risk of worsening jaw problems. The medical oncologist, dentist, and oral surgeon work closely together to make these decisions. In some cases, doctors may consider whether to continue, modify, or temporarily pause the bone-protecting medications, always keeping in mind that these drugs play an important role in preventing serious bone complications from cancer.^[2]

For people with more advanced osteonecrosis who don’t respond to conservative treatment, or whose dead bone has spread significantly, surgical intervention may become necessary. Surgical debridement involves removing the dead bone tissue. This procedure is performed by an oral surgeon who carefully scrapes away or cuts out the necrotic bone while trying to preserve as much healthy tissue as possible. In some cases, surgeons inject platelet-rich fibrin into the wound after removing dead bone. This substance, made from the patient’s own blood, contains growth factors that can help stimulate healing of the surrounding tissue.^[16]

The length of treatment varies considerably. Some patients see improvement within weeks of starting conservative therapy, while others require months of ongoing care. Approximately half of patients with early-stage osteonecrosis can be healed through non-surgical methods alone. However, more advanced cases may require surgical treatment and prolonged follow-up care. Regular monitoring by both dental and medical specialists continues even after the active symptoms resolve, as the condition can sometimes return.^[16]

Treatment in Clinical Trials

While standard treatments help many patients with osteonecrosis of the jaw, researchers recognize that current approaches are not always satisfactory, particularly for advanced cases. This has led to exploration of new treatment strategies in clinical trials and research settings. Scientists are investigating various innovative approaches to improve outcomes and quality of life for affected patients.

Research into the underlying mechanisms of medication-related osteonecrosis has revealed that the condition involves multiple biological processes. The medications that most commonly cause this condition—bisphosphonates like zoledronic acid (Zometa) and alendronate (Fosamax), as well as denosumab (Prolia, Xgeva)—work by blocking the cells called osteoclasts that normally break down bone. While this helps prevent bone loss and reduces fractures, it can also interfere with the jaw’s natural ability to repair the tiny damage that occurs from everyday chewing and dental procedures. Research suggests these drugs may also reduce blood vessel formation in the jaw, contributing to bone death.^[3]

Clinical investigations have focused on understanding why the jaw is particularly vulnerable compared to other bones. The jaw undergoes more frequent remodeling than other bones because of the constant stress from chewing and the proximity to teeth. The teeth are separated from the jawbone by only a small ligament, which means bacteria from the mouth can more easily affect the bone. These insights help researchers develop targeted treatments that address the specific vulnerabilities of jaw tissue.^[16]

Studies have examined the role of preventive dental care in reducing the incidence of osteonecrosis. Research has shown that patients who receive thorough dental examinations and complete necessary dental treatments before starting bisphosphonate or denosumab therapy have significantly lower rates of developing jaw osteonecrosis. This has led to the development of preventive protocols in many cancer centers, where dental oncology teams work alongside medical oncologists to optimize oral health before and during treatment with bone-modifying agents.^[23]

Researchers are investigating whether temporarily stopping bisphosphonate medications before dental procedures might reduce risk. However, studies to date have not shown clear evidence that “drug holidays” prevent osteonecrosis or improve healing. The drugs, particularly bisphosphonates, remain in bone tissue for very long periods—sometimes years—after the last dose, which means stopping them shortly before a dental procedure may not be helpful. This remains an active area of investigation.^[3]

Clinical trials have explored different surgical techniques for treating established osteonecrosis. Some surgeons are testing minimally invasive approaches that remove only the most obviously dead bone, while others investigate more extensive resection of affected areas. Research has examined the use of hyperbaric oxygen therapy, where patients breathe pure oxygen in a pressurized chamber, though evidence for its effectiveness in medication-related osteonecrosis remains limited. Studies continue to refine surgical protocols to determine the optimal timing and extent of bone removal.^[14]

Investigations into risk factors have helped identify which patients are at highest risk for developing osteonecrosis. Studies have found that patients receiving intravenous bisphosphonates for cancer treatment face a much higher risk—between 1% and 5%—compared to those taking oral bisphosphonates for osteoporosis, whose risk is less than 0.1%. Other risk factors identified through research include older age, diabetes, smoking, gum disease, and concurrent use of corticosteroids or chemotherapy. Understanding these risk factors helps doctors identify patients who need especially careful monitoring and preventive care.^[3]

Recent research has identified that other cancer treatments beyond traditional bone-modifying agents can also cause osteonecrosis. Antiangiogenic medications, which block the formation of new blood vessels that tumors need to grow, have been associated with jaw osteonecrosis. Examples include bevacizumab (Avastin) and sunitinib. Some immunotherapy agents and targeted therapies used in cancer treatment have also been linked to this complication, though less commonly. These findings have expanded awareness of which patients need careful dental monitoring.^[4]

A 2024 study found that approximately 8% of women with breast cancer who received bisphosphonates or denosumab developed osteonecrosis of the jaw. This rate was higher than previously reported in earlier studies. Women who received a bisphosphonate followed by denosumab had the highest rates of developing this condition, while those who received only denosumab developed it earlier in their treatment course. These findings highlight the need for continued research into optimal treatment strategies and preventive approaches for patients requiring these medications.^[17]

Staging Systems and Treatment Planning

Doctors use a staging system to classify how advanced osteonecrosis of the jaw is, which helps them determine the most appropriate treatment approach. The most widely used classification system was developed by the American Association of Oral and Maxillofacial Surgery. Stage 0 describes patients taking bone-modifying medications who have nonspecific jaw pain but no visible exposed bone. Stage 1 occurs when there is exposed dead bone visible in the mouth, but little to no pain. Stage 2 involves exposed dead bone that has become infected and painful. Stage 3 represents the most advanced disease, where dead bone has spread beyond the area next to the teeth and may cause jawbone fractures or spread into the sinuses.^[16]

The staging helps guide treatment decisions. Patients with Stage 0 or Stage 1 disease typically receive conservative treatment with mouth rinses and antibiotics. Many of these patients—approximately half—will heal without surgery. Patients with Stage 2 disease may need more intensive antibiotic therapy and closer monitoring. Those with Stage 3 disease often require surgical removal of the dead bone because conservative treatments are less likely to be effective at this advanced stage.^[22]

Most common treatment methods

• Conservative medical management
  • Antibiotics to control bacterial infections affecting the exposed jawbone
  • Antimicrobial mouth rinses used multiple times daily to reduce oral bacteria
  • Pain medications (analgesics) to control discomfort
  • Gentle debridement using cotton swabs to clean exposed bone
• Dental support therapies
  • Custom mouth guards to protect exposed bone areas
  • Regular professional dental cleaning to maintain oral health
  • Conservative dental procedures when possible (such as root canals instead of extractions)
• Medication management
  • Evaluation of whether to continue, modify, or pause bone-modifying agents in consultation with oncologists
  • Coordination between cancer treatment needs and jaw health risks
• Surgical interventions
  • Surgical debridement to remove dead bone tissue
  • Platelet-rich fibrin injection to promote healing using growth factors from patient’s own blood
  • Minimally invasive techniques to preserve healthy tissue
• Preventive strategies
  • Comprehensive dental examination and treatment before starting bone-modifying medications
  • Regular dental monitoring during and after treatment
  • Patient education about symptoms and oral hygiene practices

Prevention and Risk Reduction

Because treating osteonecrosis of the jaw can be challenging, prevention is extremely important. The most effective preventive strategy is completing a thorough dental evaluation and any necessary dental work before starting medications that increase risk. This means having teeth cleaned, cavities filled, and any infected teeth treated or removed before beginning bisphosphonate or denosumab therapy. Allowing the mouth to heal completely from dental procedures before starting these medications can significantly reduce the risk of developing osteonecrosis.^[2]

Maintaining excellent oral hygiene during treatment is equally important. This includes brushing teeth after every meal, flossing daily, and using antimicrobial mouth rinses as recommended. Regular dental check-ups every few months allow dentists to catch and treat problems early before they require more invasive procedures. Patients should inform their dentist immediately about any mouth pain, loose teeth, or sores that don’t heal within two weeks.^[3]

When dental procedures become necessary during treatment with bone-modifying medications, dentists try to use the most conservative approaches possible. For example, performing a root canal to save a tooth is preferable to extracting it. Full-mouth extractions and extensive periodontal surgery should be avoided if possible. Patients with gum disease should consider non-surgical treatments before choosing surgery. These strategies help minimize trauma to the jaw that could trigger osteonecrosis.^[3]